Kazia Therapeutics Secures $10M Stock Purchase Agreement

TL;DR

Kazia just inked a $10M stock deal with Alumni Capital for flexible funding.

AI Summary

On April 19, 2024, Kazia Therapeutics Limited entered into a purchase agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its common stock. This agreement provides Kazia with flexible access to capital to fund its ongoing operations and development programs.

Why It Matters

This agreement provides Kazia Therapeutics with a flexible source of capital, which can be crucial for funding clinical trials and advancing its drug development pipeline.

Risk Assessment

Risk Level: medium — The company is entering into a stock purchase agreement, which can dilute existing shareholders and is subject to market conditions.

Key Numbers

• $10.0M — Stock Purchase Facility (Maximum amount Kazia can raise from Alumni Capital under the agreement.)

Key Players & Entities

• Kazia Therapeutics Limited (company) — Registrant
• Alumni Capital LP (company) — Purchaser
• $10 million (dollar_amount) — Maximum value of stock to be sold
• April 19, 2024 (date) — Date of Purchase Agreement

FAQ

Key Financial Figures

• $15,000,000 — ompany may sell to Alumni Capital up to $15,000,000 (the Investment Amount), of American De
• $6,000,000 — rcise price is variable and is equal to $6,000,000 divided by the number of outstanding Or
• $0.204 — April 19, 2024, the exercise price was $0.204. Alumni Capital may exercise the Warran
• $500,000 — any single business day no greater than $500,000 in ADSs ($1,000,000 for the initial pur
• $1,000,000 — s day no greater than $500,000 in ADSs ($1,000,000 for the initial purchase thereunder), u
• $2,500,000 — apital, up to an amount no greater than $2,500,000. The purchase price in respect of any p

Filing Documents

• d830350d6k.htm (6-K) — 15KB
• d830350dex41.htm (EX-4.1) — 107KB
• d830350dex101.htm (EX-10.1) — 275KB
• 0001193125-24-102940.txt ( ) — 398KB

From the Filing

Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INFORMATION CONTAINED IN THIS FORM 6-K REPORT On April 19, 2024, Kazia Therapeutics Limited (the Company) entered into a purchase agreement (the Purchase Agreement) with Alumni Capital LP (Alumni Capital). Pursuant to the Purchase Agreement, the Company may sell to Alumni Capital up to $15,000,000 (the Investment Amount), of American Depositary Shares (ADSs), representing fully paid ordinary shares, no par value (Ordinary Shares), with each ADS representing ten Ordinary Shares (the Purchase Notice Securities), from time to time during the term of the Purchase Agreement. The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. Pursuant to the Purchase Agreement, the Company also agreed to file a registration statement with the Securities and Exchange Commission (the SEC), covering the resale of the ADSs issued or sold to Alumni Capital under the Purchase Agreement under the Securities Act of 1933, as amended (the Registration Statement). In consideration for Alumni Capitals execution and delivery of the Purchase Agreement, the Company shall issue a warrant to Alumni Capital (the Warrant), valid for a term of three (3) years, entitling Alumni Capital to purchase ADSs (the Warrant ADSs) with a value (calculated based on the then-current ADS to Ordinary Share ratio) equal to five percent (5%) of the Investment Amount. The Warrant exercise price is variable and is equal to $6,000,000 divided by the number of outstanding Ordinary Shares as of the time of exercise, multiplied by the then-current ADS to Ordinary Share ratio. On April 19, 2024, the exercise price was $0.204. Alumni Capital may exercise the Warrant on a cashless basis if the Company does not maintain an effective registration statement for the resale of the Warrant ADSs. The Company cannot issue any ADSs to Alumni Capital until the date that the Registration Statement is declared effective by the SEC and a final prospectus in connection therewith is filed and all of the other conditions set forth in the Purchase Agreement are satisfied (such date, the Commencement Date). The Company shall have no right to issue any Purchase Notice Securities and Alumni Capital shall have no obligation to purchase any Purchase Notice ADSs if the issuance of the underlying Ordinary Shares underlying such Purchase Notice Securities would result in Alumni Capital and its associates holding more than 19.9% of the Companys outstanding Ordinary Shares (the Exchange Cap), unless the Company obtains shareholder approval to issue ADSs in excess of the Exchange Cap. Beginning on the Commencement Date and until December 31, 2025, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Companys discretion, the Company has the right, but not the obligation, to issue to Alumni Capital, and Alumni Capital is obligated to purchase, the Purchase Notice Securities, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time, from and after the Commencement Date, the Company may, at its discretion, direct Alumni Capital to purchase on any single business day no greater than $500,000 in ADSs ($1,000,000 for the initial purchase thereunder), unless waived upon mutual discretion between the Company and Alumni Capital, up to an amount no greater than $2,500,000. The purchase price in respect of any purchase notice shall equal the lowest traded price of the ADSs during the five business days prior to the closing of any purchase thereunder, multiplied by 95% (90% for the initial purchase pursuant to the Purchase Agreement). The Purchase Agreement also prohibits the Company from directing Alumni Capital to purchase any ADSs if those ADSs, when aggregated with all other ADSs and Ordinary Shares then beneficially owned by Alumni Capital and its affiliates, would result in Alumni Capital and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding Ordinary Shares. The Purchase Agreement will automatically terminate on the earlier of (i) December 31, 2025; or (ii) the date that, pursuant to or within the meaning of any Bankruptcy Law (as defined in the Purchase Agreement), the Company commences a voluntary case or any person commences a proceeding against the

View Full Filing

View this 6-K filing on SEC EDGAR